Immune-Targeted Radiopharmaceuticals Built on LFA-1 Biology
Our Pipeline
Uncovering Infection and Inflammation at the Source
Uncovering Infection and
Inflammation at the Source
Immune-Targeted Radiopharmaceuticals Built on LFA-1 Biology
iSeek Biopharma is advancing a pipeline of immune-targeted radiopharmaceutical assets built on LFA-1 biology. The company's lead clinical program, LEUKOPET™, is designed to image activated leukocytes using PET, with the goal of improving diagnostic utility in infection and inflammation. The company's lead candidate, [⁶⁴Cu]IS1051, is being advanced through the PUREVIEW First-in-Human Phase 1 study. A second imaging candidate, [⁶⁴Cu]IS3000, supports the next-generation TRUVIEW program and extends the platform into additional applications.
Beyond infection imaging, iSeek Biopharma is advancing ORION, an immuno-oncology theranostic program. ORION pairs [⁶⁴Cu]IS3000 for diagnostic imaging with [177Lu]IS3010 and [225Ac]IS3010 for therapy, and is designed to enable both visualization and treatment of disease harnessing the same underlying LFA-1 biology.
| Program | Candidate | Focus Area | Study | Discovery | Pre-Clinical | Phase 1* | Phase 2+ | Next Milestone |
|---|---|---|---|---|---|---|---|---|
|
LEUKOPET™
Infection Imaging Program
|
[⁶⁴Cu]IS1051 | Infection Imaging |
PUREVIEW
First-in-Human
Phase 1 Study |
|
First-in-Human Phase 1 Planned 2026 |
|||
|
Imaging activated leukocytes to support diagnostic utility in infection
|
[⁶⁴Cu]IS3000 | Next-Generation Infection Imaging |
TRUVIEW
First-in-Human
Study |
|
First-in-Human Anticipated 2027 |
|||
|
ORION
Immuno-Oncology Theranostic Program
|
[⁶⁴Cu]IS3000 | Immuno-Oncology Diagnostic Imaging |
INSIGHT
Immuno-Oncology
Imaging Study |
Preclinical / Translational |
||||
|
Targeting the same underlying LFA-1 biology for diagnosis and therapy, to support patient selection and treatment
|
[¹⁷⁷Lu]IS3010 and [²²⁵Ac]IS3010 |
Immuno-Oncology Therapeutic |
ENGAGE
Immuno-Oncology
Therapeutic Study |
|
Preclinical Proof of Concept |
|||
The LEUKOPET™ Path
Advancing a best-in-class infection imaging program to improve diagnostic clarity and clinical decision-making.
Targets activated leukocytes
(LFA-1)
Localizes immune response
in infection
PET imaging for
diagnostic utility
Improved clinical
decision-making
The ORION Theranostic Pair
One target. Two complementary development candidates.
Designed to enable visualization and potential treatment.
[⁶⁴Cu]IS3000
(Visualize)
[¹⁷⁷Lu]IS3010 and
[²²⁵Ac]IS3010
(Treat)
All programs are investigational and not approved for any indication.
iSeek Biopharma is advancing a pipeline of immune-targeted radiopharmaceutical assets built on LFA-1 biology. The company’s lead clinical program, LEUKOPET™, is designed to image activated leukocytes using PET, with the goal of improving diagnostic utility in infection and inflammation. The company’s lead candidate, [⁶⁴Cu]IS1051, is being advanced through the PUREVIEW First-in-Human Phase 1 study. A second imaging candidate, [⁶⁴Cu]IS3000, supports the next-generation TRUVIEW program and extends the platform into additional applications.
Beyond infection imaging, iSeek Biopharma is advancing ORION, an immuno-oncology theranostic program. ORION pairs [⁶⁴Cu]IS3000 for diagnostic imaging with [177Lu]IS3010 and [225Ac]IS3010 for therapy, and is designed to enable both visualization and treatment of disease harnessing the same underlying LFA-1 biology.
LEUKOPETTM
Infection Imaging Program
Candidate: [⁶⁴Cu]IS1051
Focus Area: Infection Imaging
Study: PUREVIEW (First-in-Human Phase 1 Study)
Phase: Phase 1
Next Milestone: First-in-Human Phase 1 Planned 2026
Imaging activated leukocytes to support diagnostic utility in infection
Candidate: [⁶⁴Cu]IS3000
Focus Area: Next-Generation Infection Imaging
Study: TRUVIEW (First-in-Human Study)
Phase: Pre-Clinical
Next Milestone: First-in-Human Anticipated 2027
ORION
Immuno-Oncology Theranostic Program
Candidate: [⁶⁴Cu]IS3000
Focus Area: Immuno-Oncology Diagnostic Imaging
Study: INSIGHT (Immuno-Oncology Imaging Study)
Phase: Pre-Clinical
Next Milestone: Preclinical / Translational
Targeting the same underlying LFA-1 biology for diagnosis and therapy, to support patient selection and treatment
Candidate: [¹⁷⁷Lu]IS3010 and [²²⁵Ac]IS3010
Focus Area: Immuno-Oncology Therapeutic
Study: ENGAGE (Immuno-Oncology Therapeutic Study)
Phase: Preclinical
Next Milestone: Preclinical Proof of Concept
The LEUKOPET™ Path
Advancing a best-in-class infection imaging program to improve diagnostic clarity and clinical decision-making.
The ORION Theranostic Pair
One target. Two complementary development candidates. Designed to enable visualization and potential treatment.
All programs are investigational and not approved for any indication.